Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. SPY
10. KNX

Go back to Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates Outlook

Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital

February 21, 2018 8:42 AM EST

BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $18.00) while maintaining a Market Perform rating.

Analyst Do Kim said they believe ENHANZE continues to provide a strong valuation floor with Janssen conducting six studies. However, PEGPH20 Phase III interim data in 4Q18 remains a key risk.

... More

Halozyme Therapeutics (HALO) PT Raised to $22 at JPMorgan

February 21, 2018 7:24 AM EST

JPMorgan raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $22.00 (from $19.00) while maintaining a Overweight rating.

... More

Halozyme Therapeutics (HALO) PT Raised to $24 at Deutsche Bank

February 21, 2018 6:55 AM EST

Deutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating following the company's 4Q earnings report. Results were in line with our expectations given the preliminary announcement of results earlier this year. +24.6% y/y royalty... More